Closed manufacturing of cell therapies is widely accepted as an
effective way to create a safer therapeutic product through reduction
of error often associated with traditional manual cell processing
techniques. In addition to closing manufacturing systems, the industry
is moving toward targeted gene delivery methods such as transfection
with CRISPR-Cas9 to achieve both performance and safety
enhancements over traditional random integration of vectors .
Thermo Fisher Scientific is developing a family of highly flexible and
modular instruments that can be digitally and physically connected
to create a closed, end-to-end cell therapy manufacturing platform.
Here, we introduce the Gibco™ CTS™ Xenon™ Electroporation System
and highlight its ability to transform your current transfection step
into one that’s closed, optimized, and scalable. To demonstrate a
transition from research and discovery to process development and
manufacturing, we compare the CTS Xenon system to the Invitrogen™
Neon™ Transfection System, a small-scale, benchtop device that is
suitable for research and early process development.